financetom
Forex World Market Business Cryptocurrency Commodities MAP
financetom
Business
financetom
/
Business
/
V2X Discloses Pricing of Secondary Stock Offering
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
V2X Discloses Pricing of Secondary Stock Offering
Nov 13, 2024 11:28 AM

06:09 AM EST, 11/13/2024 (MT Newswires) -- V2X (VVX) said late Tuesday a certain selling stockholder priced an underwritten public stock offering at $61 per common share.

The selling stockholder has also granted the underwriters an option to buy up to 375,000 additional shares. The offering is expected to close by Thursday.

The company is not selling any shares and will not receive any proceeds from the offering.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Landis+gyr Divests EMEA Business To Aurelius For An Enterprise Value Of $215 Million
BRIEF-Landis+gyr Divests EMEA Business To Aurelius For An Enterprise Value Of $215 Million
Sep 28, 2025
Sept 29 (Reuters) - Landis+Gyr Group AG: * LANDIS+GYR GROUP AG- LANDIS+GYR DIVESTS EMEA BUSINESS TO AURELIUS * LANDIS+GYR GROUP AG-ENTERED INTO SHARE PURCHASE AGREEMENT TO DIVEST OPERATIONS IN EUROPE, MIDDLE EAST AND AFRICA TO AURELIUS FOR AN ENTERPRISE VALUE OF $215 MILLION * LANDIS+GYR-DEAL TO RESULT IN A PROVISIONAL NON-CASH IMPAIRMENT CHARGE RELATED TO CARRYING VALUE OF EMEA BUSINESS...
 Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
Sep 28, 2025
Company Announcement Genmab ( GMAB ) to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billionProposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab ( GMAB ) to host a conference...
 Lupin Strengthens its Global Specialty Ophthalmology Business with Acquisition of VISUfarma from GHO Capital
Lupin Strengthens its Global Specialty Ophthalmology Business with Acquisition of VISUfarma from GHO Capital
Sep 28, 2025
LONDON, ROME and ZUG, Switzerland, Sept. 29, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) , today announced its wholly owned subsidiary, Nanomi B.V. ('Nanomi'), has signed a definitive agreement for the acquisition of VISUfarma B.V. (VISUfarma), a portfolio company of global healthcare specialist investor GHO Capital Partners LLP (GHO). The acquisition of VISUfarma,...
 Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
Sep 28, 2025
Company Announcement Genmab ( GMAB ) to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab ( GMAB ) to host a...
About
Terms and Conditions Privacy policy Cookie Settings Contact Us
Services
Login register
financetom Market Personal Finance Business Economy Cryptocurrency MAP
Links
zpostcode Recruit weather mreligion Yellowpages sport constellation shopping name game directory literature Word tour furnish Lottery tftnews lyrics News digital car dir Edu Finance
Copyright 2023-2026 - www.financetom.com All Rights Reserved